Opthea (ASX:OPT) said there remains material uncertainty as to its ability to continue as a "going concern" as it continues to be in active negotiations with its development funding agreement investors, according to a Monday Australian bourse filing.

The management plans to hold an investor call to discuss the phase three trial results and the next steps of the firm once the negotiations with the investors have been concluded.

In the same filing, the company said Julia Haller, Susan Orr, Quinton Oswald, and Anshul Thakral resigned as directors, effective Monday, to streamline the governance in the wake of negative phase three trial results and a 65% reduction in workforce.